Pharmacyte Biotech Inc (OTCMKTS:PMCB) released an update on its efforts to get PharmaCyte’s pancreatic cancer treatment into a Phase 2b clinical trial. In the update PharmaCyte’s CEO, Kenneth L. Waggoner, explains why predictable ‘start date’ for PharmaCyte’s clinical trial in pancreatic cancer remains difficult to announce with certainty and addresses a number of issues that PharmaCyte’s shareholders have raised related to the upcoming clinical trial. ‘First and foremost, there is the issue of the redesign of the clinical trial in pancreatic cancer.
To show success originally deinked examination would contain involved hundreds of patients, taken years to complete and would have been so expensive to conduct that only “big pharma” could have afforded to carry it out successfully. With invaluable input from three of the world’s leading authorities in pancreatic cancer, the trial was completely redeinked to what it is recently.
Koninklijke Philips N.V (NYSE:PHG) [Trend Analysis] trade finished at $25.29 as shares surging 1.40%. Royal Philips (PHG) reported four leading U.S. health systems have inked multi-year telehealth accords with Philips to implement its remote intensive care unit (eICU) program. These new population health management engagements include contracts with Westchester Medical Center Health Network (WMCHealth in New York), Baptist Memorial Health Care (Tennessee) and BJC HealthCare (Missouri), and will additional extend Philips’ eICU reach by hundreds of beds and thousands of ICU cases each year. . As took noticed on firm performance, its weekly performance was 6.80%, monthly performance was 2.89%. The stock price of PHG is moving up from its 20 days moving average with 0.35% and isolated negatively from 50 days moving average with -0.13%.
Why NYSE:PHG on Bearish Notes in Eye of Experts? Find Out Here
Superior Energy Services, Inc. (NYSE:SPN) [Trend Analysis] stock finished trading at $9.53 in last trading day. Superior Energy Services, Inc. (SPN) reported that an adjusted net loss from continuing operations for the fourth quarter of 2015 of $61.3 million, or $0.41 per share, not comprising special items, on income of $545.2 million. This compares to an adjusted net loss from continuing operations of $68.8 million, or $0.46 per share, not comprising special items, for the third quarter of 2015, on income of $601.4 million, and net income from continuing operations of $73.4 million, or $0.48 per diluted share, for the fourth quarter of 2014, on income of $1,178.6 million. The reported loss from continuing operations for the fourth quarter of 2015 was $214.5 million, or $1.43 per share. The stock has a 52-week high price of $-63.98% and its 52-week low was recorded at $15.53%.
How NYSE:SPN Taste Ups And Down- Read Considerable Report Here